Results from second study cite Prolaris® as most clinically significant prognostic parameter of outcomes at time of diagnosis, identifying men who need aggressive hormonal treatment and those who can safely be monitored instead Results from second study cite Prolaris® as most clinically significant prognostic parameter of outcomes at time of diagnosis, identifying men who need aggressive hormonal treatment and those who can safely be monitored instead
Read this article:
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for...
Related Post
- EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 - March 1st, 2021
- Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021 - March 1st, 2021
- MacroGenics to Participate in Upcoming Investor Conferences - March 1st, 2021
- Cronos Group Reports 2020 Fourth Quarter and Full-Year Results - March 1st, 2021
- GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis... - March 1st, 2021
- Golden Leaf Holdings Enters into Letter of Intent to Acquire Retail Chain - March 1st, 2021
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update - March 1st, 2021
- Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B... - March 1st, 2021
- Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - March 1st, 2021
- SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results - March 1st, 2021
- Molecular Templates to Participate in Upcoming Virtual Investor Conferences - March 1st, 2021
- ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American... - March 1st, 2021
- electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia - March 1st, 2021
- BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce... - March 1st, 2021
- Annual financial report 2020 - March 1st, 2021
- Idorsia submits NDA for clazosentan to Japanese PMDA - March 1st, 2021
- Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial - March 1st, 2021
- Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China - March 1st, 2021
- Orphazyme appoints Christophe Bourdon as Chief Executive Officer - March 1st, 2021
- Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - February 27th, 2021
- Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer - February 27th, 2021
- Albireo Spotlights Global Patient Communities on Rare Disease Day - February 27th, 2021
- Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan - February 27th, 2021
- Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE - February 27th, 2021
- Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients - February 27th, 2021
- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization... - February 27th, 2021
- Genetic Technologies Limited Interview to Air on Bloomberg TV in the US on the RedChip Money Report® - February 27th, 2021
- Supernus to Present at Cowen Healthcare Conference - February 27th, 2021
- Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients - February 27th, 2021
- Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany - February 27th, 2021
- UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use... - February 27th, 2021
- GENFIT: Revenues and Cash Position as of December 31, 2020 - February 27th, 2021
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab - February 27th, 2021
- Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences - February 27th, 2021
- Orphazyme announces participation in upcoming virtual investor conferences - February 27th, 2021
- NextCure to Host Virtual R&D Update Event on March 4, 2021 - February 27th, 2021
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - February 27th, 2021
- Zomedica Corp. Announces Year End 2020 Financial Results - February 27th, 2021
- Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights - February 27th, 2021
- Quotient Limited Announces Manuel Mendez as Chief Executive Officer - February 23rd, 2021
- AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer - February 23rd, 2021
- Notice for the Annual General Meeting of Novo Nordisk A/S - February 23rd, 2021
- Agios to Present at March Investor Conferences - February 23rd, 2021
- Recro Announces Amendment to Athyrium Credit Facility - February 23rd, 2021
- Coya Therapeutics™ Announces Formation of Scientific Advisory Board - February 23rd, 2021
- Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences - February 23rd, 2021
- Kraig Biocraft Laboratories receives its first-ever Spider Silk shipment from its Vietnamese production facility - February 23rd, 2021
- iTeos to Present at Upcoming Investor Conferences in March - February 23rd, 2021
- Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial... - February 23rd, 2021
- BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary - February 23rd, 2021
- Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference - February 23rd, 2021
- PolyPid to Participate in Upcoming Investor Conferences - February 23rd, 2021
- AgraFlora Organics Announces anticipated First Sales and Revenue for Summer 2021 - February 23rd, 2021
- Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection - February 23rd, 2021
- Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021 - February 23rd, 2021
- Black Diamond Therapeutics to Present at Upcoming Investor Conferences - February 23rd, 2021
- Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference - February 23rd, 2021
- European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis... - February 23rd, 2021
- TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with... - February 23rd, 2021
- GBT Announces Participation in Upcoming Investor Conferences - February 21st, 2021
- Assembly Bio Announces Upcoming Investor Events - February 21st, 2021
- RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 21st, 2021
- BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i... - February 21st, 2021
- Intercept to Present at Upcoming Investor Conferences - February 21st, 2021
- Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates - February 21st, 2021
- Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform - February 21st, 2021
- Information expressed in the public domain by the Repharm Group is deceptive and contradictory - February 21st, 2021
- Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on... - February 21st, 2021
- CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology - February 21st, 2021
- Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan - February 21st, 2021
- Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million - February 21st, 2021
- Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares - February 21st, 2021
- Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting - February 21st, 2021
- Ayala Pharmaceuticals Announces $25 Million Strategic Financing - February 21st, 2021
- Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 - February 21st, 2021
- Tauriga Sciences Inc. Officially Launches Two New Product Offerings on its E-Commerce Platform (www.taurigum.com) - February 21st, 2021
- Iterum Therapeutics to Present in Upcoming Investor Conferences - February 21st, 2021
- Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26 - February 21st, 2021
- Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference - February 21st, 2021
- Anteris Technologies to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference - February 17th, 2021
Recent Comments